Subtype
Castration-Resistant Prostate Carcinoma
CI-CAN-00007376CRPCExplore in graph →
222 active trials12 approved drugs15 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007376CRPCExplore in graph →
Clinical trials
553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (94)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02380274 | Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)(TRUMPET) | completed | — | 1,030 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03724747 | Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 | 63 | BayerINDUSTRY |
| 3 |
| Nov 8, 2024 |
| clinicaltrials |
| NCT03414034 | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | Cardiff OncologyINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT03776968 | A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics | completed | Phase 1 | 47 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT02495974 | European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)(PREMISE) | completed | — | 1,763 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Oct 21, 2024 | clinicaltrials |
| NCT05655715 | Checkpoint Inhibitors and SBRT for MCRPC(CheckPRO) | completed | Phase 2 | 90 | Herlev and Gentofte HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03204812 | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04060394 | Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | completed | Phase 1 / Phase 2 | 49 | Laekna LimitedINDUSTRY | 2 | Oct 10, 2024 | clinicaltrials |
| NCT02099864 | Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy | completed | Phase 2 | 36 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02566772 | Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 | 130 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 3, 2024 | clinicaltrials |
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 28, 2024 | clinicaltrials |
| NCT04408924 | Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer(CYCLONE 1) | completed | Phase 2 | 44 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 25, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT05127850 | MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer | completed | N/A | 51 | University of California, San FranciscoOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT04028388 | ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer | completed | Phase 2 | 135 | Modra PharmaceuticalsINDUSTRY | 6 | Apr 17, 2024 | clinicaltrials |
| NCT04089553 | An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer | completed | Phase 2 | 59 | AstraZenecaINDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03835533 | Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations(PORTER) | completed | Phase 1 | 43 | Parker Institute for Cancer ImmunotherapyOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05252364 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 22 | Hinova Pharmaceuticals Aus Pty LtdINDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03554317 | COMbination of Bipolar Androgen Therapy and Nivolumab(COMBAT-CRPC) | completed | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03658486 | Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial(EXACT) | completed | N/A | 30 | Queen's University, BelfastOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT03878823 | Safety and Pharmacokinetics of ODM-209(STESIDES) | completed | Phase 1 / Phase 2 | 38 | Orion Corporation, Orion PharmaINDUSTRY | 3 | Feb 1, 2024 | clinicaltrials |
| NCT04887506 | TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | completed | Phase 3 | 107 | Tavanta TherapeuticsINDUSTRY | 8 | Jan 16, 2024 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT01972217 | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | completed | Phase 2 | 158 | AstraZenecaINDUSTRY | 11 | Nov 14, 2023 | clinicaltrials |
| NCT03176381 | Tissue Predictors of Abiraterone Benefit | completed | — | 110 | Tianjin Medical University Second HospitalOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02578797 | A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study | completed | Phase 1 | 45 | Aragon Pharmaceuticals, Inc.INDUSTRY | 5 | Nov 9, 2023 | clinicaltrials |
| NCT03751436 | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT02987543 | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | completed | Phase 3 | 387 | AstraZenecaINDUSTRY | 20 | Oct 6, 2023 | clinicaltrials |
| NCT05725070 | Phase 0/1 Study of 212Pb-NG001 in mCRPC | completed | Early Phase 1 | 3 | ARTBIO Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04000776 | 3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer | completed | — | 100 | Université de SherbrookeOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT03658447 | PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)(PRINCE) | completed | Phase 1 / Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jul 28, 2023 | clinicaltrials |
| NCT03569280 | Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients | completed | Phase 1 | 16 | Kangpu Biopharmaceuticals, Ltd.INDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT03456804 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 13 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05549778 | Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC(PEACe) | completed | Phase 1 / Phase 2 | 12 | Jiangnan UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04179396 | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)(RAMP) | completed | Phase 1 | 8 | pharmaand GmbHINDUSTRY | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04676607 | SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON2) | completed | Phase 2 | 277 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT03406858 | Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 15 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04962880 | HRR Prevalence in LatAm PROSPECT Study(PROSPECT) | completed | — | 388 | AstraZenecaINDUSTRY | 7 | Apr 14, 2023 | clinicaltrials |
| NCT02833883 | Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer | completed | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02907372 | Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer(COG-PRO) | completed | N/A | 163 | Centre Francois BaclesseOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT02669147 | A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC(DELC) | completed | — | 160 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 0 | Dec 28, 2022 | clinicaltrials |
| NCT03526562 | Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients | completed | N/A | 9 | University Hospital, GhentOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02598895 | Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway | completed | Phase 2 | 14 | University of WashingtonOTHER | 1 | Nov 17, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Nov 20, 2024source: clinicaltrials